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Letter to the Editor 
Low prevalence of ectopic germinal center formation in patients with 
HTLV-I-associated Sjögren’s syndrome.  
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SIR, We have proposed that HTLV-I infection can be a possible environmental factor 
for SS based on high prevalence of anti-HTLV-I Ab in pSS in Nagasaki (1-3), and 
recently confirmed that LSGs of the HTLV-I-seropositive SS patients are less 
damaged in radiography (4). Amft et al (5) revealed prominent expression of 
B-cell-attracting chemokine 1 (BCA-1/CXCL13) on endothelial cells and lymphocytic 
aggregates in the ectopic germinal center (GC) of labial salivary glands (LSGs) in SS, 
speculating that ectopic GC is associated with the autoantibodies production as well as 
the salivary destruction (5).   
We focused on the presence of ectopic GC formation in situ as well as the 
expression of CXCL 12/CXCL 13. Sixty-four pSS patients were entried and 
classification of pSS was determined by the revised criteria proposed by the 
American-European Consensus group (6). LSGs from a control subject who 
complained of sicca but did not meet the pSS criteria have been obtained. The 
presence of anti-HTLV-I Ab was determined by enzyme-linked immunosorbent assay 
(ELISA; Eitest-ATL kit; Esai, Tokyo, Japan) or particle agglutination assay 
(Serodia-ATL Kit; Fujirebio, Tokyo, Japan). Informed consent for the usage of 
samples obtained by the biopsy was obtained from all the participating patients as of 
the commencement of the study, and the study was conducted with the approval of the 
human ethical committee of our institution. Immunohistochemistry was performed by 
the labeled streptavidin-biotin method (Histofine Staining Kit, Nichirei Co., Tokyo, 
Japan) using mouse anti-CXCL 12 monoclonal Ab or goat anti-CXCL 13 polyclonal 
Ab (R&D Systems Inc., Minneapolis, MN, USA) (2) with microwave epitope retrieval 
for the detection of CXCL13. Negative control sections were treated with normal 
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mouse IgG or normal goat serum. Mann-Whitney’s U test, the Chi-square test or 
Fisher’s exact probability test were used for statistical analysis. A P value less than 
0.05 was statistically significant. 
The gender and age were similar in 32 HTLV-I-seronegative (M/F;3/29, 
age;56.9 ±14.9) and 32 HTLV-I-seropositive (M/F;4/28, age;58.5 ±12.6) pSS patients, 
as well as in 9 HTLV-I-associated myelopathy (HAM)-pSS patients (M/F;1/8, 
age;61.6 ±8.9). Sicca symptoms were observed in 83.3%-100% of patients among the 
groups. Differences in anti-SS-A/SS-B Abs (Mesacup SS-A/Ro test and SS-B/La Test; 
Medical & Biological Laboratories, Nagoya, Japan) and IgG concentrations at the 
time of biopsy were not statistically significant irrespective of  HTLV-I infection. 
Strikingly, ectopic GC was low in HTLV-I-seropositive pSS (1/32, 3.1%) as compared 
with HTLV-I-seronegative pSS (6/32, 18.8%) (p=0.045), and 0% in HAM-pSS.  
Expression of CXCL13 was observed in 0-10 % of MNCs of 
HTLV-I-seronegative pSS without ectopic GC patients or HTLV-I-seropositive pSS 
patients (Fig. 1). In HTLV-I-seronegative pSS (N = 6) with ectopic GC patients, the 
expression of CXCL13 was found dominantly in the light zone of ectopic GC. All of 
the cases showed more than 50 % of MNCs in the light zone of ectopic GC expressing 
CXCL13. One pSS in HTLV-I carrier showed a relatively small size of ectopic GC 
whose CXCL 13 expression pattern was similar. However, interestingly, the MNCs of 
HAM-pSS patients demonstrated no expression of CXCL13. In contrast to CXCL 13, 
CXCL12 was commonly expressed on ductal epithelial cells of all the pSS patients 
irrespective of anti-HTLV-I Ab. In a normal subject, no expression of CXCL13 was 
observed with positive expression of CXCL 12 similar with pSS.  
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The lymphoid aggregates of LSGs are responsible for autoantibodies 
production that is locally occurred in ectopic GC (5, 7, 8). Radiographic destruction of 
the ductal structure in HTLV-I-seropositive pSS occurs to a lesser extent than in 
HTLV-I-seronegative pSS, which is a unique characteristic of the former (4).   
  The chemokines have been found to regulate ectopic GC formation of SS (5). 
Xanthou et al (9) also demonstrated significance of lymphoid chemokines for 
lymphoid structure formation in SS while others have demonstrated an association of 
CXCL 13 expression and ectopic GC formation in SS (7, 8). Barone et al found a 
B-cell-dominant expression pattern (8), whereas the selected expression in acinar and 
ductal epithelial cells was observed by Salomonsson et al. (7), although the exact roles 
of these results remain unclear.  
Our data suggest an important interaction of CXCL 13 and ectopic GC in 
sialadenitis in SS. The tendency toward low levels of radiographic damage in patients 
with HAM-pSS suggests that salivary-specific cytotoxicity is modified by HTLV-I 
infection. Due to even expression of CXCL 12 irrespective of HTLV-I infection, 
HTLV-I presumably affects the CXCL 13 expression of infected CD4+ T cells. Via 
inflammatory mediators modulated by HTLV-I Tax protein, dysfunction of 
MNC-lineage cells due to HTLV-I infection is supposed to play an important role. 
 
Key message 
Low prevalence of ectopic GC formation is one of the characteristics of 
HTLV-I-seropositive SS patients associated with CXCL 13 on MNCs. 
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Figure legends 
Figure 1 Expression of CXCL13 and CXCL12 in HTLV-I-seronegative and 
HTLV-I-seropositive patients with Sjögren’s syndrome (SS) 
Immunohistochemical analysis of CXCL 13 (BCA-1) in minor labial salivary glands 
(LSGs) was demonstrated (A-D). After pretreatment with microwave epitope retrieval, 
goat anti-CXCL 13 polyclonal antibody was used to detect the expression of CXCL13. 
Expression of CXCL12 (SDF-1) was examined using mouse anti-CXCL 12 
monoclonal antibody (E-H). A and E. Expression of CXCL 13 and CXCL 12 in minor 
LSG from an HTLV-I-seronegative SS patient with ectopic germinal center (GC). B 
and F. Expression of CXCL 13 and CXCL 12 in minor LSG from an 
HTLV-I-seronegative SS patient without GC. C and G. Expression of CXCL 13 and 
CXCL 12 in minor LSG from an HTLV-I-seropositive SS patient without GC. These 
are representative case of 5 patients with HTLV-I-seronegative SS with ectopic GC, 
HTLV-I-seronegative SS patients without ectopic GC, and HTLV-I-seropositive SS 
patients without GC, respectively. D and H. Expression of CXCL 13 and CXCL 12 in 
minor LSG from an HTLV-I-associated myelopathy (HAM)-SS patient. I and J. 
Expression of CXCL13 and CXCL12 in minor LSG section from a normal subject, 
respectively. K and L. Expression of CXCL 13 in the light zone and CXCL 12 in 
mantle zone of human tonsil tissue as a positive control, respectively. Hematoxylin 
and Methyl green were used for counterstaining of CXCL13 and CXCL12, 
respectively. (Original magnification x 100) 
 

